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ABSTRACT: The development of covalent ligands for G protein-
coupled receptors (GPCRs) is not a trivial process. Here, we report
a streamlined workflow thereto from synthesis to validation,
exemplified by the discovery of a covalent antagonist for the
human adenosine A3 receptor (hA3AR). Based on the 1H,3H-
pyrido[2,1-f ]purine-2,4-dione scaffold, a series of ligands bearing a
fluorosulfonyl warhead and a varying linker was synthesized. This
series was subjected to an affinity screen, revealing compound 17b
as the most potent antagonist. In addition, a nonreactive
methylsulfonyl derivative 19 was developed as a reversible control
compound. A series of assays, comprising time-dependent affinity
determination, washout experiments, and [35S]GTPγS binding
assays, then validated 17b as the covalent antagonist. A combined in
silico hA3AR-homology model and site-directed mutagenesis study was performed to demonstrate that amino acid residue
Y2657.36 was the unique anchor point of the covalent interaction. This workflow might be applied to other GPCRs to guide the
discovery of covalent ligands.
■ INTRODUCTION
The adenosine A3 receptor (A3AR) is one of four G protein-
coupled receptor subtypes stimulated by adenosine.1 Different
from the other subtypes (A1, A2A, and A2B) A3AR was
identified by molecular biology studies prior to its pharmaco-
logical characterization.2 The initial studies indicated its
important role in both physiological and pathophysiological
conditions, such as cell proliferation, cell differentiation,
neuroprotection, cardioprotection, and apoptosis.3 Never-
theless, the medical relevance of the human adenosine A3
receptor (hA3AR) is enigmatic due to its dichotomy in
different therapeutic applications.3 In this regard, there is a
continuing interest in the development of selective ligands of
the hA3AR to investigate its pharmacological effects. For
instance, selective A3AR antagonists have been applied for the
treatment of glaucoma4 and respiratory tract inflammation
such as asthma.5 In particular, a tricyclic xanthine derivative, 1-
benzyl-8-methoxy-3-propyl-1H,3H-pyrido[2,1-f ]purine-2,4-
dione (compound 1, Figure 1A), has been reported to exert
high affinity for the hA3AR.
6−8
Initial efforts to study the structural biology of GPCRs
suffered from numerous limitations, such as low expression,
dynamic conformational states, and inherent instability.
Covalent ligands, i.e., compounds that irreversibly bind to
the receptor and possess a reactive moiety to target specific
amino acid residues, helped to solve some of these obstacles.9
This is also the case for adenosine receptors. For example, the
structure of the human adenosine A1 receptor, having the
highest similarity to the hA3AR among all adenosine receptor
subtypes (61% of sequence homology),10 has been elucidated
by X-ray crystallography with a covalent antagonist DU172 (2)
(Figure 1B).11 However, the application of covalent ligands in
hA3AR studies has been limited to the characterization of the
receptor type,12−14 far from providing a comprehensive study
of receptor structure elucidation, pharmacological character-
istics, and ligand−receptor binding description.
To this end, we devoted our efforts to the discovery of a
well-defined covalent antagonist based on xanthine analogue 1
mentioned above. Inspired by the resemblance in the chemical
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Figure 1. (A) Reference antagonist (1) for hA3AR. (B) DU172 (2), a
covalent antagonist for hA1AR.
Article
pubs.acs.org/jmcCite This: J. Med. Chem. 2019, 62, 3539−3552
© 2019 American Chemical Society 3539 DOI: 10.1021/acs.jmedchem.8b02026
J. Med. Chem. 2019, 62, 3539−3552
This is an open access article published under a Creative Commons Non-Commercial No
Derivative Works (CC-BY-NC-ND) Attribution License, which permits copying and























































































structure between the potent hA3AR antagonist 1 and
irreversible adenosine A1 receptor antagonist 2, we incorpo-
rated the reactive moiety, a fluorosulfonyl benzoyl group,
connected to a spacer, at the N1 position of the scaffold. Using
a structured approach to bring the reactive fluorosulfonyl
group in close proximity to a nucleophilic amino acid residue,
we diversified the type of linker, linker length, and position of
the fluorosulfonyl substituent on the phenyl group, resulting in
a series of analogues with a wide range of affinities. Our efforts
led to the discovery of a best-in-class antagonist, 17b, which is
bound to the hA3AR with an apparent affinity in the
nanomolar range. To retain the chemical structure similarity,
we replaced the warhead with a methylsulfonyl moiety to
obtain a nonreactive derivative 19 as a reversible control
compound. 17b was then validated to covalently bind and
inactivate the hA3AR in an insurmountable manner. Molecular
modeling suggested the fluorosulfonyl functionality of 17b in
close proximity to Y2657.36, which was identified as the unique
anchor point of the covalent interaction in a subsequent
mutagenesis study. The confirmed binding mode between this
novel covalent antagonist and hA3AR opens the door for
exploring other ligand binding motifs and will benefit receptor
stabilization and further structure elucidation of the hA3AR.
■ RESULTS AND DISCUSSION
Design of Covalent hA3AR Antagonists. In previous
studies, our research group disclosed several series of hA3AR
antagonists based on the pyrido[2,1-f ]purine-2,4-dione scaf-
fold.6−8 Using compound 1, a nanomolar probe from the
previous series, as the starting point, we further designed and
synthesized compounds based on a previously suggested
binding mode of the pyrido[2,1-f ]purine-2,4-dione scaffold.7
When examining the suggested binding mode of this scaffold,
we noted that this scaffold inserted into the binding pocket
with a receptor interaction between TM3, TM6, and EL2. Two
key H-bonds include the carbonyl-oxygen at the C4-position
with residue N2506.55 and the methoxy substituent at the C8-
position bonding to Q167EL2. Taking this into account, we
reasoned that the only available space to incorporate the
reactive warhead is limited to N1-position substituents.
To explore the chemical space required to optimally position
the warhead in close proximity to a nucleophilic amino acid
residue, we examined various linker systems, connecting the
warhead and the pyrido[2,1-f ]purine-2,4-dione scaffold. First,
variation in the length of the spacer, between two and four
carbon atoms, may offer more steric freedom allowing the
fluorosulfonyl group to orient toward an adjacent nucleophilic
residue in the receptor binding site.15,16 Additionally, the type
of chemical bond connecting the warhead to the spacer was
varied between the slightly differently oriented ester or amide
Scheme 1. Synthetic Route toward Scaffold 7a
aReagents and conditions: (a) (i) Ac2O, 80 °C, 2 h; (ii) Et2O, room temperature (rt), 1 h; (iii) 3 M NaOH, 85 °C, 1 h; (iv) HCl (37%), 25%; (b)
(i) NBS, MeCN, 80 oC; (ii) 4-methoxypyridine, 80 °C, 64%; (c) 1-bromopropane, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), MeCN, 70 °C,
73%; (d) Pd(OH)2/C, HCOONH4, EtOH, reflux, 40%.
Scheme 2. Synthetic Route toward the Bromoalkyl Fluorosulfonylbenzoates 13a−c and 14a−ca
aReagents and conditions: (a) 2 M KHF2 solution, dioxane, rt, 1 h, 87−90%; (b) SOCl2 reflux; (c) corresponding bromoalkylalcohol, anhydrous
dioxane, 100 °C, 18h, 55−83%, (d) 11a−c or 12a−c, K2CO3, anhydrous DMF, 50 °C, 5−57%.
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bond. Finally, since the exact position of an appropriate
nucleophilic residue is unknown, the sulfonyl fluoride moiety
was positioned at either the 3- or 4-position of the phenyl ring.
To this end, four series of compounds 13a−c, 14a−c, 17a−c,
and 18a−c, bearing three different spacer lengths, ester or
amide linkage, and 3- or 4-fluorosulfonylphenyl warhead were
targeted for synthesis.
Synthesis. Scaffold. The scaffold, 8-methoxy-3-propyl-
1H,3H-pyrido-[2,1-f ]purine-2, 4-dione (1), was synthesized
according to the previously published procedure.6−8 Starting
from the commercially available benzylurea (3), the fused
tricyclic intermediate (6) was generated by excess N-
bromosuccinimide (NBS) bromination and 4-methoxypyridine
cyclization (Scheme 1). Then, alkylation at the N3-nitrogen by
1-bromopropane in dry dimethylformamide (DMF), using dry
potassium carbonate as a weak base, afforded the reference
compound (1) in 73% yield. Removing the benzyl protecting
group by palladium hydroxide afforded the fused xanthine core
(7).
Ester Linker. The fluorosulfonyl warhead is notorious for its
reactivity, resulting in undesired side reactions or hydrolysis
under several harsh reactions.17 So, we adopted a convergent
synthetic strategy in which the fluorosulfonylphenyl linker unit
was prepared separately and attached directly to scaffold 7 at
the N3 position. This approach offers flexibility to accom-
modate a variety of different linker lengths. The warhead was
synthesized from commercially available chlorosulfonylbenzoic
acids (8a and 8b) (Scheme 2), followed by a 2 M solution of
potassium bifluoride treatment to afford fluorosulfonylbenzoic
acids (9a and 9b) in good yields.18 The next step converted
the carboxylic acids to acid chlorides (10a and 10b) by excess
thionyl chloride treatment. These acyl chlorides are susceptible
to hydrolysis and were thus used in the next step reaction
without further purification. To incorporate the acyl chlorides
with the corresponding bromoalkylalcohols, compounds 10a
and 10b were heated to 100 °C with the addition of
bromoalkylalcohols to afford the desired bromoalkyl fluo-
rosulfonylbenzoates (11a−c and 12a−c) in decent yields. The
final step was to couple the core to the corresponding
bromoalkyl fluorosulfonylbenzoates. To preserve the func-
tional fluorosulfonyl group, the reactions were carried out
under mild conditions at low temperatures. Additionally,
Scheme 3. Synthetic Route toward the Amide-Linker Antagonists 17a−c, 18a−c, and 19a
aReagents and conditions: (a) N-(bromoalkyl)phthalimide, K2CO3, DMF, 100 °C, 5−96%; (b) N2H4·H2O, MeOH reflux, 86−90%; (c) 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (EDC), corresponding acid (9a,b), CHCl3 or CH2Cl2, rt; and (d) SOCl2, K2CO3, dry DMF, 40 °C, 3−78%
Table 1. Apparent Affinities of Pyrido[2,1-f ]purine-2,4-dione Derivatives 13−19
compound n X R1 pKi ± SEM
a or disp. at 10 μm (%)
13a 1 O 4-SO2F 6.7 ± 0.1
13b 2 O 4-SO2F 7.7 ± 0.1
13c 3 O 4-SO2F 7.5 ± 0.1
14a 1 O 3-SO2F 6.4 ± 0.1
14b 2 O 3-SO2F 7.0 ± 0.05
14c 3 O 3-SO2F 7.1 ± 0.05
17a 1 NH 4-SO2F 27%
17b (LUF7602) 2 NH 4-SO2F 8.0 ± 0.05
17c 3 NH 4-SO2F 7.5 ± 0.05
18a 1 NH 3-SO2F 18%
18b 2 NH 3-SO2F 7.5 ± 0.01
18c 3 NH 3-SO2F 6.8 ± 0.1
19 (LUF7714) 2 NH 4-SO2Me 6.3 ± 0.03
aData are expressed as means ± standard error of the mean (SEM) of three separate experiments each performed in duplicate. Apparent affinity
determined from the displacement of specific [3H]PSB-11 binding from the hA3AR stably expressed on Chinese hamster ovary (CHO) cell
membranes at 25 °C during 2 h of incubation.
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excess DMF was removed by multiple washing steps, instead of
vacuum removal at high temperatures. Six final products
(13a−c and 14a−c) were obtained in acceptable yields.
Amide Linker. A similar synthetic approach was initially
pursued to prepare analogues with an amide linker. However,
the basicity and instability of bromoalkylamine caused complex
side reactions with itself and with the warhead, ending up with
an unacceptably low yield of amide-linked building blocks. An
alternative synthetic route was devised, where 1-phthalimido-
propyl bromide was attached directly to the N3 position of
scaffold 6, to afford the substituted intermediates 15a−c
(Scheme 3). Liberation of the amine took place by treatment
with hydrazine monohydrate in methanol to obtain compound
16a−c in moderate yield. Then 16b and 16c were acylated
with acyl chlorides 10a and 10b, respectively, to obtain 17c
and 18b. However, impurities brought by the acylation
reaction were not easily removed by column chromatography
or preparative thin-layer chromatography (TLC). To over-
come this, we used peptide coupling conditions with the
corresponding benzoic acids (9a and 9b) to convert the free
amine to the target compounds (17a,b, 18a, and 18c) in good
yields (Scheme 3). A similar synthetic strategy was adapted to
obtain reversible ligand 19 as a control compound.
Pharmacological Evaluation. Determination of the
Apparent Affinity (Ki) of Synthetized Ligands. To determine
the binding affinity for the hA3AR, all compounds were tested
in a radioligand displacement binding assay in the presence of
10 nM [3H]PSB-11 at 25 °C according to previously reported
procedures.7,19 All compounds were able to concentration-
dependently inhibit specific [3H]PSB-11 binding to the
hA3AR. As detailed in Table 1, all putative covalent
compounds, except the two carbon linker compounds (13a,
14a, 17a, and 18a), displayed high affinities for the hA3AR (Ki
< 100 nM). It should be mentioned that the putative covalent
nature of the interaction between the hA3AR and ligands
precludes the determination of equilibrium binding parame-
ters. Therefore, we expressed the ligands’ affinity for the
hA3AR as “apparent Ki”. Of note, 17b, bearing three carbon
atoms with amide linkage and positioning the sulfonyl fluoride
at the 4-position of the phenyl ring, interacted with the hA3AR
with comparable affinity (10 nM) as the parent compound 1.
High affinity is desirable for covalent ligand design, as it allows
sufficient receptor occupancy with the electrophilic warhead in
proximity to a nucleophilic residue in the binding site over
time, concomitant with putatively negligible or less interaction
with off-targets. Thus, we chose compound 17b for further
studies. However, featuring an electrophilic fluorosulfonyl
functionality, 17b was no longer a close analogue of compound
1, whereas a nonreactive control compound, chemically similar
to the designed covalent ligand, is needed for the further
pharmacological characterization.
A nonsubstituted phenyl to replace the warhead might
impose different steric and electronic characteristics of the
ligand. To avoid this, we performed a conservative structural
modification to replace the reactive warhead with an electron-
withdrawing methylsulfonyl group, yielding derivative 19 as a
nonreactive control compound.








cpd pKi ± SEM displ. (%) at 1 μm pKi
e (pre-0 h) pKi
f (pre-4 h) pIC50 ± SEM
f
17bi 6.1 ± 0.03 5.9 ± 0.09 0% (7, −7) 6.9 ± 0.06 8.0 ± 0.01** 7.8 ± 0.05 6.0 ± 0.3*
19 4.8 ± 0.20 5.2 ± 0.20 0% (−10, −13) 6.2 ± 0.03 6.1 ± 0.06NS 5.9 ± 0.02 6.1 ± 0.1NS
aValues represent mean ± SEM of three separate experiments, each performed in duplicate, or percentage displacement at 1 μm of two separate
experiments, each performed in duplicate. bAffinity determined from the displacement of specific [3H]DPCPX binding on CHO cell membranes
stably expressing human adenosine A1 receptors at 25 °C during 2 h of incubation.
cAffinity determined from the displacement of specific
[3H]ZM241385 binding on HEK293 cell membranes stably expressing human adenosine A2A receptors at 25 °C during 2 h of incubation.
d%
displacement at 1 μm concentration of specific [3H]PSB-603 binding on CHO cell membranes stably expressing human adenosine A2B receptors at
25 °C during 2 h of incubation. eDisplacement of specific [3H]PSB-11 binding on CHO cell membranes stably expressing the hA3AR at 25 °C
during 0.5 h of incubation. fDisplacement of specific [3H]PSB-11 binding from CHO cell membranes stably expressing the hA3AR preincubated
with an antagonist for 4 h at 25 °C, followed by a 0.5 h of co-incubation with [3H]PSB-11. P < 0.01** compared with the pKi values in
displacement experiments during 0.5 h of incubation time; NS: no significant difference compared with the pKi values in displacement experiments
during 0.5 h of incubation time; Student’s test. gDisplacement of specific [3H]PSB-11 binding from CHO-K1 cell membranes transiently
transfected with hA3AR-WT at 25 °C during 2 h of incubation.
hDisplacement of specific [3H]PSB-11 binding from CHO-K1 cell membranes
transiently transfected with hA3AR-Y265F
7.36 at 25 °C during 2 h of incubation. P < 0.01* compared with the pIC50 values in displacement
experiments on hA3AR-WT. NS: no significant difference compared with the pIC50 values in displacement experiments on hA3AR-WT membranes;
Student’s test. iFor 17b, pKi values are apparent affinity values as no dynamic equilibrium can be obtained.
Figure 2. (A) Displacement of [3H]PSB-11 binding from the hA3AR at 25 °C by 17b with and without preincubation of 4 h. (B) Displacement of
[3H]PSB-11 binding from the hA3AR at 25 °C by 19 with and without preincubation of 4 h. Data represent the mean ± SEM of three individual
experiments performed in duplicate.
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To better understand the time-dependent binding character-
istics of these compounds, we carried out radioligand
displacement assays under two different protocols. In detail,
the CHO cell membranes overexpressing the hA3AR were
either preincubated with the indicated compound for 4 h,
followed by a 0.5 h co-incubation or only co-incubated for 0.5
h with the radioligand [3H]PSB-11. As detailed in Table 2,
both compounds had comparable binding affinity in the low
micromolar range (pKi = 6.9 ± 0.06 for 17b and pKi = 6.2 ±
0.03 for 19) at 0.5 h incubation time. However, compound
17b showed a significantly increased affinity (pKi = 8.0 ± 0.01)
when it was preincubated with the hA3AR, whereas the affinity
of compound 19 did not change (pKi = 6.1 ± 0.06). The effect
of preincubation on the affinity of 17b and 19 is illustrated in
Figure 2, i.e., the [3H]PSB-11 displacement curve was shifted
to the left with an increased incubation time for compound
17b (Figure 2A), whereas no difference was observed for
compound 19 (Figure 2B).
Presumably, this time-dependent binding affinity of
compound 17b (i.e., resulting from an increased receptor
occupancy over time) is a result of an increasing level of
covalent binding. Similar results on other GPCRs, such as β2
adrenergic receptor20 and A2A adenosine receptor,
21 showed
that covalent bond formation generates an increased affinity
over time. Meanwhile, control compound 19 showed no
substantial pKi shift in affinity at the two incubation times,
indicating that a dynamic equilibrium was achieved at both
incubation times. We can thus speculate that the possible
covalent interaction between compound 17b and the receptor
may be attributed to the presence of a reactive warhead.
Finally, we tested 17b and 19 for their affinity on the other
adenosine receptor subtypes and learned that the two
compounds were at least modestly selective for the hA3AR
(Table 2).
Kinetic Characterization of the Covalent Ligand. Sub-
sequently, the significant shift in apparent Ki drove us to
explore the binding kinetic profile of 17b at the hA3AR,
specifically its dissociation rate and residence time (RT).
Previously, the kon (k1 = 0.281 ± 0.04 × 10
8 M−1 min−1) and
koff (k2 = 0.3992 ± 0.02 min
−1) values of [3H]PSB-11 at 25 °C
had been determined in our laboratory by traditional
association and dissociation assays. Here, we performed a
competition association assay to characterize the binding
kinetics of 17b and 19 following previously reported
procedures from our research group.7 Using the on- and off-
rate constants from [3H]PSB, the kon (k3) and koff (k4) values
for 17b were determined using the equations from the
(equilibrium) Motulsky and Mahan model.22 17b had a much
slower association rate (kon = 3.48 ± 0.22 × 10
5 M−1 min−1)
than the radioligand and a negligible dissociation rate (koff =
1.38 ± 0.22 × 10−12 min−1), yielding an almost infinite
residence time (RT = 7.63 ± 1.19 × 1011 min), indicative of
irreversible receptor binding by 17b. The inadequacy of the
Motulsky−Mahan equations to fit this data is further evidence
for the nonequilibrium features of the binding of 17b to the
receptor. Compound 19 showed fast association and
dissociation rate constants (Figure 3). Unfortunately, the
data did not converge in the fitting procedure, possibly due to
the low binding affinity of compound 19 (Ki = 525 nM).
As detailed in Figure 3, the control curve represented the
association curve of radioligand [3H]PSB-11 alone, approach-
ing equilibrium over time. Compound 19 equally associated
with and dissociated from the receptor and reached
equilibrium within 30 min, evidenced by the same curve
shape as the control curve. Of note, 17b’s behavior caused an
initial “overshoot” of the competition association curve,
followed by a linear decline over time indicating that no
equilibrium was reached. The shape of 17b’s kinetic curve is a
quintessential example for the irreversible interaction, similar
to the reported covalent ligands’ behavior for the adenosine
A2A receptor
21 and mGlu2 receptor.23
Wash-Resistant Interaction between 17b and hA3AR.
Inspired by the negligible dissociation of compound 17b from
the hA3AR, we performed a “washout” experiment to ascertain
the irreversible binding between the ligand and the receptor. A
protocol previously reported by our laboratory21 was adapted.
We first exposed hA3AR cell membranes to 17b or 19 both at
10-fold Ki for 2 h, and without washing the samples were
supplemented with [3H]PSB-11 to assess the competitive
binding capacity of the receptor (“control group” in Figure 4).
For washed samples, hA3AR cell membranes were subjected to
four-cycle washing steps to remove unbound ligand following
the preincubation (“4× wash group” in Figure 4), after which
the membranes were exposed to [3H]PSB-11 to determine the
remaining binding capacity. In the absence of the ligand
(labeled “+ vehicle” in Figure 4), we normalized membranes’
binding ability to 100%. Following preincubation with 17b,
membranes containing the hA3AR lost most of the ability to
bind to the radioligand (11.3 ± 1.2% binding remaining).
Furthermore, after the preincubation, membranes were washed
by cycles of centrifugation in an attempt to regenerate binding
Figure 3. Competition association assay of [3H]PSB-11 in the
absence (control) or presence of 17b and 19 at the indicated
concentration. Association and dissociation rate constants for the
unlabeled ligands were calculated by fitting the data to the equations
described in the Experimental Section (“data analysis”). Representa-
tive graphs are from one experiment performed in duplicate.
Figure 4. hA3AR membranes preincubated with buffer (vehicle) or a
10 × Ki concentration of indicated ligand, followed by no washing
(control) or four-cycle washing treatment (4× wash) before being
exposed to [3H]PSB-11. Data represent the mean ± SEM of three
individual experiments performed in duplicate, normalized to the
vehicle (set at 100%). Statistics were determined using unpaired
Student’s t-test. NS: no significant difference, ****P < 0.0001,
significant difference between indicated groups.
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capacity. However, washing steps failed to restore hA3AR
binding of [3H]PSB-11 (8.7 ± 3.8%). This was in contrast to
preincubation of the hA3AR-expressing membranes with ligand
19, in which binding function was completely restored from
19.8 ± 4.7 to 97.6 ± 4.5% following four washing steps. This
result indicates that 19 is a reversible ligand which can be
rapidly washed off the membranes, whereas 17b forms a wash-
resistant bond between the ligand and the receptor. Similar
experiments on other GPCRs, such as adenosine A1
24,25 and
A2A
21 receptors and the metabotropic glutamate receptor 2
(mGluR2),23 demonstrated that the covalent interaction
between the ligand and the receptor resulted in a wash-
resistant bond formation.
Insurmountable Antagonism Caused by Covalent Inter-
action. To further evaluate the effect of irreversible inhibition
by covalent ligand 17b on receptor function, we performed a
membrane functional assay using [35S]GTPγS, which is a
typical readout for the activation of receptor-coupled Gi/o
proteins.26 Pretreatment of the hA3AR with increasing
concentrations of ligand 17b, prior to the stimulation with
hA3AR agonist 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-
9H-purin-9-yl]-1-deoxy-N-methyl-β-D-ribofuranuronamide (2-
Cl-IB-MECA), produced rightward shifts of agonist concen-
tration−response curves with a concomitant decline in
maximal stimulation (Figure 5A). Therefore, the covalent
ligand 17b generated insurmountable antagonism in the
preincubation experiment. In contrast, pretreatment of the
hA3AR with 19, followed by 2-Cl-IB-MECA agonist exposure
resulted in surmountable antagonism (Figure 5B), i.e., shifting
dose−response curves to the right with no alteration of its
maximum effect. The extent of the shifts was used to construct
a Schild plot as previously described,7 which would have a
slope of unity if the interaction is competitive and the pA2-
value corresponds to the pKi value of the antagonist. The slope
for 19 was found to be 1.1 ± 0.1 and the compound’s pA2
value was 5.9 ± 0.1, comparable with its pKi value (6.3 ±
0.03), suggesting that 19 competed with 2-Cl-IB-MECA for
the same receptor binding site.
To unravel the molecular mechanism responsible for the
insurmountable antagonism of 17b, we also co-incubated
either 17b or 19 with the hA3AR in the presence of 2-Cl-IB-
MECA. Both ligands produced a rightward shift of the
agonist’s concentration−response curve (Figure 5C,D) with no
suppression of maximal response, indicative of surmountable
Figure 5. Effects of 17b and 19 on hA3AR activation as measured by [
35S]GTPγS binding. (A, B) Compound 17b (A) or 19 (B) was preincubated
with the hA3AR stably expressed on CHO cell membranes (25 °C) for 60 min prior to the addition of 2-Cl-IB-MECA at a concentration ranging
from 0.1 nM to 10 μm for 30 min. (C, D) Compound 17b (C) or 19 (D) were co-incubated with 2-Cl-IB-MECA, at a concentration ranging from
0.1 nM to 10 μm, for 30 min. The agonist curves were generated in the presence of increasing concentrations of antagonists, such as 0.3-, 1-, 3-, and
10-fold Ki values, respectively. Data are from three independent experiments performed in duplicate, normalized according to the maximal response
(100%) produced by 10 μm 2-Cl-IB-MECA alone. The shift in agonist EC50 values was determined to perform Schild analyses.
Table 3. Functional Analysis of hA3AR Antagonism from [
35S]GTPγS Binding Assaysa
preincubation co-incubation
compound pA2 Schild slope pA2 Schild slope mode of antagonism
17b NA NA 7.4 ± 0.1 1.1 ± 0.1 competitive insurmountable
19 5.9 ± 0.1 1.1 ± 0.1 6.2 ± 0.1 1.0 ± 0.1 competitive surmountable
aValues represent mean ± SEM of three separate experiments each performed in duplicate.
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antagonism. The Schild plot showed that both antagonists
inhibited receptor activation in a competitive manner, with
their Schild-slopes close to unity (1.1 ± 0.1 for 17b, 1.0 ± 0.1
for 19, Table 3). In addition, 19’s pA2 value was in agreement
with that from the preincubation experiments (6.2 ± 0.1, Table
3), and the pA2 value of 17b was also comparable with its pKi
value (7.4 ± 0.1 vs 8.0 ± 0.05). Taken together, both ligands
fully competed with 2-Cl-IB-MECA bound to the hA3AR.
Notably, it is likely that the insurmountable behavior relates to
the covalent binding of 17b due to an irreversible blockade
that reduces the total receptor population available.
Binding Model for 17b in the hA3AR Receptor-Binding
Pocket. To examine the interaction between receptor residues
possibly involved in covalent binding, we docked 17b into a
ligand optimized homology model on the basis of the A2A
receptor crystal structure (PDB: 4EIY27), as described
Figure 6. Proposed binding mode of compound 17b (green carbon sticks) in a homology model (violet ribbons) of the hA3AR. The hA3AR
homology model was based on the high-resolution antagonist-bound crystal structure of the adenosine A2A receptor (PDB: 4EIY
27). Atom color
code: red = oxygen, blue = nitrogen, white = hydrogen, yellow = sulfur, cyan = fluorine. Hydrogen bonds between the ligand and receptor are
indicated by yellow dashed lines. Residue Y2657.36 is in the proximity of the fluorosulfonyl warhead.
Figure 7. (A, B) Displacement of specific [3H]PSB-11 binding from transiently transfected hA3AR-WT and hA3AR-Y265F
7.36 at 25 °C by
compound 17b (A) and 19 (B) during incubation of 2 h. (C) hA3AR-Y265F
7.36 cell membranes were pretreated with buffer (vehicle) or 10 × IC50
of compound 17b for 2 h followed by no washing (control) or four-cycle washing treatment (4× wash) before being exposed to [3H]PSB-11. Data
represent the mean ± SEM of three individual experiments performed in duplicate, normalized to the vehicle (set at 100%). NS: no significant
difference between groups; ***Significant difference between groups (P < 0.001); Student’s t-test.
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previously.7 As detailed in Figure 6, the core structure of
compound 17b interacted with the TM3, TM6, and EL2
regions. Additionally, the carbonyl-oxygen at the C4-position
participated in H-bond formation with residue N2506.55 and
the methoxyl moiety at the C8-position functioned as H-bond
acceptor with Q167EL2. Interestingly, the latter is a unique
residue in the hA3AR, as it is not conserved in other subtypes
of adenosine receptors. Due to the flexibility of the three
carbon linkers, the tyrosine residue Y2657.36 is in close
proximity of the ligand, and could therefore interact with the
4-fluorosulfonylbenzoic warhead to form a covalent sulfonyl
amide. Similarly, the same residue Y2717.36 located within the
human adenosine A1 receptor has also been reported to
covalently interact with the fluorosulfonyl warhead of
compound 2.11 Comparison of the binding modes of
compound 2 and ligand 17b in an A1/A3 receptor overlay
showed that key interactions between ligands and binding sites
are preserved, such as a hydrogen bond with N6.55 (Figure S1).
Y2657.36 as an Anchor Point for the Covalent Bond. Based
on the docking study, we postulated that Y2657.36 is the anchor
point for covalent bond formation. To investigate our
hypothesis this tyrosine was mutated to phenylalanine
(hA3AR-Y265F
7.36), to remove the nucleophilic reactivity of
the phenolic hydroxyl group. First, we performed standard
[3H]PSB-11 displacement assays to investigate the binding
affinity of 17b and 19 using CHO-K1 cell membranes
transiently transfected with either wild type (hA3AR-WT) or
mutant receptors (hA3AR-Y265F
7.36). As shown in Table 2 and
Figure 7, the affinity of control compound 19 on hA3AR-
Y265F7.36 (pIC50 = 6.09 ± 0.11) was similar to the affinity to
hA3AR-WT (pIC50 = 5.95 ± 0.03), indicating that the
mutation has no impact on the binding affinity of the
reversible ligand. In marked contrast, 17b’s affinity was
decreased nearly 43-fold relative to the WT, from an IC50
value of 27 to 1072 nM, indicative of the loss of irreversible
interaction. Moreover, there were no marked affinity differ-
ences on hA3AR-Y265F
7.36 between 17b and 19. This suggests
that the chemically dissimilar ligands 17b (reactive) and 19
(nonreactive) exhibit a similar binding interaction with hA3AR-
Y265F7.36. We thus speculate that the amino acid in position
7.36 plays a prominent role in the covalent bond formation
between the fluorosulfonyl warhead and the receptor. To
support this idea, we repeated the washout assay on hA3AR-
Y265F7.36. Membranes treated with 17b at 10-fold IC50
inhibited the specific [3H]PSB-11 binding to 7.2 ± 0.6%.
After extensive washing, hA3AR-Y265F
7.36 showed a complete
recovery of [3H]PSB-11 binding to 91 ± 2% (Figure 7C). This
full recovery for mutant hA3AR-Y265F
7.36 is in sharp contrast
to the findings in the wild-type washout assay (Figure 4),
indicating that Y265F7.36 completely prevented the wash-
resistant bond formation. In other words, Y2657.36 is the
unique amino acid residue involved in the covalent attachment
of 17b’s fluorosulfonyl group within the hA3AR binding
pocket. A similar approach was also adopted to pinpoint the
anchor point between covalent probes and other subtypes of
GPCRs, such as the adenosine A2A receptor,
21 mGlu2
receptor,23 and cannabinoid CB1 receptor.
28
17b can be a useful structural biology tool as it would be
expected to stabilize the 7TM domain in its inactive state,
thereby potentially facilitating crystallization of the receptor
material. This could be highly valuable for the structure
elucidation of the hA3AR, which up to now remains
unreported. Furthermore, understanding the precise molecular
interactions between the ligand and the receptor may stimulate
the more rational design of novel ligands. Such ligands may
have improved receptor subtype selectivity, fewer undesirable
side effects, and enhanced potency and efficacy, leading to
potentially attractive therapeutic agents that produce their
effects by modulating the functionality of the adenosine
system. Given that GPCR-targeted covalent drugs went
through clinical success across various indications,29 our
covalent compound 17b may serve as a probe to explore the
problematic translation of hA3AR ligands into the clinical
utility in certain disease states such as eye disorder glaucoma,
in which an increased A3 adenosine receptor mRNA and
protein levels have been detected.
■ CONCLUSIONS
By introducing a reactive sulfonyl fluoride warhead onto the 1-
benzyl-3-propyl-1H,3H-pyrido [2,1-f ]purine-2,4-dione scaf-
fold, we designed and synthesized a series of novel covalent
hA3AR antagonists. Compound 17b acted as the most potent
antagonist, with a time-dependent apparent affinity in the low
nanomolar range. Meanwhile, we removed the warhead and
inserted a methylsulfonyl moiety into the scaffold, to obtain
ligand 19 as a reversible control compound. Ligand 17b was
then validated as a covalent antagonist through its wash-
resistant nature and insurmountable antagonism in
[35S]GTPγS binding assays. In silico homology-docking
suggested that Y2657.36 is responsible for the covalent
interaction. Site-directed mutagenesis showed that removal of
the nucleophilic tyrosine phenolic hydroxyl group resulted in
the complete loss of covalent binding, validating that Y2657.36
is the only anchor point of reactive covalent ligand 17b. The
results contribute to a better understanding of pharmacological
behaviors caused by covalent interaction with GPCRs. In the
end, we developed a structured approach to quickly obtain a
well-defined covalent ligand. Besides, we envisioned that a
methylsulfonyl replacement would be suitable for providing a
nonreactive sulfonyl-bearing control compound. The rational
design of covalent probes may have further value in receptor
structure elucidation or in new technologies such as affinity-
based protein profiling15,30 with the perspective of imaging or
structurally probing GPCRs.
■ EXPERIMENTAL SECTION
Chemistry. All solvents and reagents were purchased from
commercial sources and were of analytical grade. Demineralized
water is simply referred to as H2O, and was used in all cases unless
stated otherwise (i.e., brine). 1H were recorded on a Bruker AV 400
liquid spectrometer (1H NMR, 400 MHz) at ambient temperature
and 13C NMR spectra were recorded on a Bruker AV 600 liquid
spectrometer (13C NMR, 125 MHz) at indicated temperature.
Chemical shifts are reported in parts per million (ppm), using
residual solvent as the internal reference in all cases. The values are
given in δ scale. Coupling-constants are reported in Hz and are
designated as J. Analytical purity of the final compounds was
determined by high-performance liquid chromatography (HPLC)
with a Phenomenex Gemini 3 μm C18 110 Å column (50 × 4.6 mm,
3 μm), measuring UV absorbance at 254 nm. Sample preparation and
the HPLC method were as follows: 0.3−1.0 mg of compound was
dissolved in 1 mL of a 1:1:1 mixture of MeCN/H2O/tBuOH and
eluted from the column within 15 min at a flow rate of 1.3 mL min−1
with a three-component system of H2O/MeCN/1% trifluoroacetyl
(TFA) in H2O. The elution method was set up as follows: 1−4 min
isocratic system of H2O/MeCN/1% TFA in H2O, 80:10:10, from the
4th min, a gradient was applied from 80:10:10 to 0:90:10 within 9
min, followed by 1 min of equilibration at 0:90:10 and 1 min at
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80:10:10. All final compounds showed a single peak at the designated
retention time and are at least 95% pure. Liquid chromatography−
mass spectrometry (LC−MS) analyses were performed using a
Thermo Finnigan Surveyor−LCQ Advantage Max LC−MS system
and a Gemini C18 Phenomenex column (50 × 4.6 mm2, 3 μm). High-
resolution mass spectrometry (HRMS) analyses were performed
using a Thermo Scientific LTQ Orbitrap XL Hybrid Ion Trap-
Orbitrap Mass Spectrometer. The sample preparation was the same as
for HPLC and HRMS analyses. The compounds were eluted from the
column within 15 min after injection, with a three-component system
of H2O/MeCN/0.2% TFA in H2O, decreasing polarity of the solvent
mixture in time from 80:10:10 to 0:90:10. Thin-layer chromatography
(TLC) was routinely performed to monitor the progress of reactions,
using aluminum-coated Merck silica gel F254 plates. Purification by
column chromatography was achieved using the Grace Davison
Davisil silica column material (LC60A 30−200 μm). Solutions were
concentrated using a Heidolph Laborota W8 2000 efficient rotary
evaporation apparatus. All reactions in the synthetic routes were
performed under a nitrogen atmosphere unless stated otherwise. The
procedure for a series of similar compounds is given as a general
procedure for all within that series, annotated by the numbers of the
compounds.
1-Benzyl-8-methoxy-3-propyl-1H,3H-pyrido[2,1-f ]purine-
2,4-dione (1).7,8 To a stirred suspension of 6 (6.0 g, 19 mmol, 1.0
equiv) in MeCN (120 mL) were added 1-bromopropane (5.6 mL, 57
mmol, 3.0 equiv) and DBU (50 mL, 57 mmol, 3.0 equiv). This
mixture was stirred at 70 °C overnight. The conversion of the starting
material was confirmed by TLC (2% MeOH in CH2Cl2) and the
solvent was removed under vacuum. The residue was suspended in
CH2Cl2 (200 mL) and the organic phase was washed with 1 M HCl
(200 mL), H2O (200 mL), and brine (200 mL), dried over MgSO4,
filtered, and concentrated in vacuo. The crude was purified by column
chromatography (0.5% MeOH in CH2Cl2) to obtain 1 as a white
solid (5.0 g, 14 mmol, 73%). 1H NMR (400 MHz, CDCl3): δ 8.82 (d,
J = 7.6 Hz, 1H), 7.58−7.51 (m, 2H), 7.34−7.22 (m, 3H), 6.98 (d, J =
2.0 Hz, 1H), 6.74 (dd, J = 7.4, 2.2 Hz, 1H), 5.36 (s, 2H), 4.04−3.97
(m, 2H), 3.92 (s, 3H), 1.76−1.65 (m, 2H), 0.97 (t, J = 7.4 Hz, 3H)
6-Amino-1-benzyl-1,3-dihydropyrimidine-2,4-dione (5).7,8
The synthesis of the compounds was performed as adapted from
the procedure reported before.7,8 Benzylurea (3) (25 g, 167 mmol, 1.0
equiv) and 4 (16 g, 191 mmol, 1.1 equiv) were dissolved in acetic
anhydride (100 mL). This mixture was stirred at 80 °C for 2 h. After
the mixture was cooled to room temperature, diethyl ether (150 mL)
was added followed by 1 h of stirring at room temperature. The
precipitate was filtered off and suspended in a mixture of EtOH (75
mL) and H2O (150 mL). This mixture was heated to 85 °C and 3 M
NaOH (aq.) (50 mL) was added dropwise. After 1 h, the mixture was
concentrated and neutralized by the dropwise addition of HCl (37%).
The precipitate was filtered off and washed with acetone, obtaining 5
as a white solid (9.0 g, 42 mmol, 25%). 1H NMR (400 MHz, DMSO-
d6): δ 10.42 (brs, 1H), 7.48−7.08 (m, 5H), 6.85 (brs, 2H), 5.03 (s,
2H), 4.60 (s, 1H)
1-Benzyl-8-methoxy-1H,3H-pyrido[2,1-f ]purine-2,4-dione
(6).7,8 To the intermediate (5) (9.0 g, 42 mmol, 1.0 equiv) and NBS
(15 g, 83 mmol, 2.0 equiv) was added MeCN (100 mL). This mixture
was stirred at 80 °C. After 1.5 h, the conversion of the starting
material was confirmed by TLC (10% MeOH in CH2Cl2), 4-
methoxypyridine (13 g, 125 mmol, 3.0 equiv) was added and the
reaction mixture was stirred at 80 °C for 4.5 h. After cooling to room
temperature, the precipitate was filtered off and washed with diethyl
ether and MeOH, yielding product 6 as a white solid (8.5 g, 26 mmol,
64%). 1H NMR (400 MHz, DMSO-d6): δ 11.31 (br s, 1H), 8.70 (d, J
= 7.2 Hz, 1H), 7.38−7.16 (m, 6H), 6.90 (dd, J = 7.4, 2.2 Hz, 1H),
5.18 (s, 2H), 3.89 (s, 3H)
8-Methoxy-3-propyl-1H,3H-pyrido[2,1-f ]purine-2,4-dione
(7).7,8 To a mixture of intermediate 1 (1.1 g, 3.0 mmol, 1.0 equiv),
Pd(OH)2/C (2.0 g, 14 mmol, 1.0 equiv), and ammonium formate
(0.20 g, 3.0 mmol, 1.0 equiv) was added EtOH (250 mL). During the
reaction, five portions of ammonium formate (0.20 g, 3.0 mmol, 1.0
equiv) was added, after which completion of the reaction was
observed by TLC (5% MeOH in CH2Cl2). The reaction was filtered
over Celite and the residue was extracted with hot DMF. Purification
of the crude product was performed by column chromatography using
2−10% MeOH in CH2Cl2 to obtain 5 as a white solid (0.30 g, 1.2
mmol, 40%). 1H NMR (400 MHz, DMSO-d6): δ 12.05 (s, 1H), 8.73
(d, J = 7.2 Hz, 1H), 7.12 (d, J = 2.0 Hz, 1H), 6.89 (dd, J = 7.4, 2.6 Hz,
1H), 3.90 (s, 3H), 3.85−3.78 (m, 2H), 1.64−1.52 (m, 2H), 0.88 (t, J
= 7.4 Hz, 3H)
General Procedure for the Synthesis of Fluorosulfonylben-
zoic Acids (9a,b). To a solution of chlorosulfonylbenzoic acid (8a,b)
(2.2 g, 10 mmol, 1.0 equiv) in dioxane (25 mL) was added a solution
of HF/KF (15 mL, 2.0 M, 3.0 equiv). The mixture was stirred at room
temperature. After 1 h, the reaction mixture was diluted with EtOAc
(80 mL). The organic phase was washed with H2O (50 mL), dried
over MgSO4, filtered, and concentrated in vacuo.
3-(Fluorosulfonyl)benzoic Acid (9a).White solid (1.9 g, 8.7 mmol,
87%). 1H NMR (400 MHz, DMSO-d6): δ 8.47−8.44 (m, 2H), 8.4 (d,
J = 8.0 Hz, 1H), 7.94 (t, J = 7.6 Hz, 1H).
4-(Fluorosulfonyl)benzoic Acid (9b).White solid (2.0 g, 9.0 mmol,
90%). 1H NMR (400 MHz, DMSO-d6): δ 13.86 (s, 1H), 8.28 (s, 4H)
General Procedure for the Synthesis of Bromoalkyl
(fluorosulfonyl)benzoates (11a−c and 12a−c). A mixture of
thionyl chloride (8 mL) and fluorosulfonylbenzoic acid (9a,b) (1
equiv) was refluxed at 75 °C for 3 h. The solvent was removed under
vacuum and the product was used in the next step without further
analysis. Dry dioxane (6 mL) was added to the (fluorosulfonyl)-
benzoyl chloride (10a,b). To this solution, the corresponding
bromoalkylalcohol (0.85 equiv) was added and the mixture was
refluxed overnight. After the completion of the reaction was observed
by TLC (CH2Cl2), the volatiles were removed in vacuo and the crude
product was purified by column chromatography using CH2Cl2 as an
eluent to afford the products.
2-Bromoethyl-4-(fluorosulfonyl)benzoate (11a). Colorless oil
(0.088 g, 0.28 mmol, 23%) 1H NMR (400 MHz, DMSO-d6): δ
8.31 (d, J = 8.2 Hz, 2H), 8.11 (d, J = 8.5 Hz, 2H), 4.69 (t, J = 5.9 Hz,
2H), 3.67 (t, J = 5.9 Hz, 2H).
3-Bromopropyl-4-(fluorosulfonyl)benzoate (11b). White solid
(2.0 g, 6.2 mmol, 50%) 1H NMR (400 MHz, CDCl3): δ 8.27 (d, J
= 8.4 Hz, 2H), 8.09 (d, J = 8.4 Hz, 2H), 4.54 (t, J = 6.0 Hz, 2H), 3.54
(d, J = 6.4 Hz, 2H), 2.35 (m, 2H).
4-Bromobutyl-4-(fluorosulfonyl)benzoate (11c). White solid
(0.30 g, 0.89 mmol, 45%) compound was used without further
purification.
2-Bromoethyl-3-(fluorosulfonyl)benzoate (12a). Colorless oil
(0.51 g, 1.7 mmol, 55%) 1H NMR (400 MHz, CDCl3): δ 8.69 (s,
1H), 8.47 (d, J = 7.6 Hz, 1H), 8.25−8.20 (m, 1H), 7.78 (t, J = 8.0 Hz,
1H), 4.71 (t, J = 6.0 Hz, 2H), 3.68 (t, J = 6.0 Hz, 2H).
3-Bromopropyl-3-(fluorosulfonyl)benzoate (12b). Colorless oil
(0.12 g, 0.38 mmol, 23%) 1H NMR (400 MHz, CDCl3) δ 8.65 (t, J =
1.6 Hz, 1H), 8.44 (d, J = 7.8 Hz, 1H), 8.21 (d, J = 8.0 Hz, 1H), 7.76
(t, J = 7.9 Hz, 1H), 4.55 (t, J = 6.1 Hz, 1H), 3.55 (t, J = 6.4 Hz, 1H),
2.37 (p, J = 6.3 Hz, 1H).
4-Bromobutyl-3-(fluorosulfonyl)benzoate (12c). Colorless Oil
(0.84 g, 2.5 mmol, 83%,) 1H NMR (400 MHz, CDCl3): δ 8.65 (s,
1H), 8.45 (d, J = 8.0 Hz, 1H), 8.21 (d, J = 8.0 Hz, 1H), 7.78 (t, J = 7.6
Hz, 1H), 4.44 (t, J = 6.0 Hz, 2H), 3.50 (t, J = 6.4 Hz, 2H), 2.11−1.85
(m, 4H).
General Procedure for the Synthesis of 13a−c and 14a−c.
The synthesis of these compounds was adapted from the conditions
previously described by Priego et al.6 The scaffolds 8-methoxy-3-
propyl-1H,3H-pyrido[2,1-f ]purine-2,4-dione 7 (1.0 equiv) and
K2CO3 (1.6 equiv) were suspended in anhydrous DMF. The mixture
was added dropwise to a stirred solution of the corresponding
bromoalkyl (fluorosulfonyl)benzoate (11a−c or 12a−c) (1.0 equiv)
in anhydrous DMF (4 mL). The reaction was stirred at 50 °C
overnight. After the conversion was observed by TLC, an excess
amount of CH2Cl2 was added. Then the mixture was washed with 1
M HCl (aq.), water, and brine. The organic layer was dried over
MgSO4, filtered, and concentrated in vacuo. The crude product was
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purified by column chromatography, followed by prep TLC to further
purify the compound if necessary.
2-(8-Methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f ]-
purine-1(2H)-yl)ethyl 4-(fluorosulfonyl)benzoate (13a). Prepared
from 11a and purified by column chromatography (1% CH3OH in
CH2Cl2) to give the desired product as a white solid (0.038 g, 0.07
mmol, 52%). 1H NMR (400 MHz, CDCl3): δ 8.80 (d, J = 8.0 Hz,
1H), 8.17 (d, J = 8.0 Hz, 2H), 7.98 (d, J = 8.4 Hz, 2H), 6.76−6.73
(m, 2H), 4.78 (t, J = 4.8 Hz, 2H), 4.64 (t, J = 5.2 Hz, 2H), 4.00 (t, J =
7.6 Hz, 2H), 3.89 (s, 3H), 1.73−1.62 (m, 2H), 0.95 (t, J = 7.2 Hz,
3H). MS: [ESI + H]+: 505.1. HPLC: 9.99 min
3-(8-Methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f ]-
purine-1(2H)-yl)propyl 4-(fluorosulfonyl)benzoate (13b). Prepared
from 11b and purified by column chromatography (1% CH3OH in
CH2Cl2) to give the desired product as a white solid (0.096 g, 0.19
mmol, 76%). 1H NMR (400 MHz, CDCl3): δ 8.76 (d, J = 7.2 Hz,
1H), 8.23 (d, J = 8.0 Hz, 2H), 8.06 (d, J = 8.4 Hz, 2H), 6.77 (d, J =
2.4 Hz, 1H), 6.73 (dd, J = 7.2, 2.4 Hz, 1H), 4.50 (t, J = 6.0 Hz, 2H),
4.41 (t, J = 6.8 Hz, 2H), 4.00 (t, J = 7.2 Hz, 2H), 3.90 (s, 3H), 2.38
(pentet, J = 6.0 Hz, 2H), 1.71 (sextet, J = 7.2 Hz, 2H), 0.99 (t, J = 7.6
Hz, 3H). MS: [ESI + H]+: 519.1. HPLC: 10.18 min
4-(8-Methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f ]-
purine-1(2H)-yl)butyl 4-(fluorosulfonyl)benzoate (13c). Prepared
from 11c and purified by column chromatography (2% CH3OH in
CH2Cl2) to give the desired product as a white solid (0.010 g, 0.019
mmol, 5.2%) 1H NMR (400 MHz, CDCl3): δ 8.83 (dd, J = 7.6, 0.8
Hz, 1H), 8.27 (d, J = 8.0 Hz, 2H), 8.07 (d, J = 8.8 Hz, 2H), 6.93 (d, J
= 2.4 Hz, 1H), 6.76 (dd, J = 7.6, 2.4 Hz, 1H), 4.46 (t, J = 6.4 Hz, 2H),
4.28 (t, J = 6.8 Hz, 2H), 4.02 (t, J = 7.2 Hz, 2H), 3.93 (s, 3H), 2.05−
1.90 (m, 4H), 1.77−1.68 (m, 2H), 0.99 (t, J = 7.2 Hz, 3H). MS: [ESI
+ H]+: 533.1. HPLC: 9.40 min
2-(8-Methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f ]-
purine-1(2H)-yl)ethyl 3-(fluorosulfonyl)benzoate (14a). Prepared
from 12a and without purification to give the desired product as a
white solid (0.19 g, 0.36 mmol, 57%). 1H NMR (400 MHz, CDCl3):
δ 8.80 (d, J = 7.2 Hz, 1H), 8.51 (s, 1H), 8.36 (d, J = 7.6 Hz, 1H),
8.14−8.09 (m, 1H), 7.66 (t, J = 7.8 Hz, 1H), 6.84 (d, J = 2.4 Hz, 1H),
6.74 (dd, J = 7.6, 2.6 Hz, 1H), 4.78 (t, J = 4.8 Hz, 2H), 4.65 (t, J = 4.8
Hz, 2H), 4.04−3.97 (m, 2H), 3.90 (s, 3H), 1.68 (sextet, J = 7.6 Hz,
2H), 0.96 (t, J = 7.4 Hz, 3H). MS: [ESI + H]+: 505.1. HPLC: 8.47
min
3-(8-Methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f ]-
purine-1(2H)-yl)propyl 3-(fluorosulfonyl)benzoate (14b). Prepared
from 12b and purified by column chromatography (1% CH3OH in
CH2Cl2) to give the desired product as a white solid (0.035 g, 0.068
mmol, 34%). 1H NMR (400 MHz, CDCl3): δ 8.74 (d, J = 7.6 Hz,
1H), 8.65 (s, 1H), 8.36 (d, J = 8.0 Hz, 1H), 8.18 (d, J = 8.0 Hz, 1H),
7.73 (t, J = 8.0 Hz, 1H), 6.86 (d, J = 2.0 Hz, 1H), 6.72 (dd, J = 7.2,
2.4 Hz, 1H), 4.51 (t, J = 6.0 Hz, 2H), 4.41 (t, J = 6.0 Hz, 2H), 3.99 (t,
J = 7.6 Hz, 2H), 3.91 (s, 3H), 2.39 (pentet, J = 6.0 Hz, 2H), 1.70
(sextet, J = 7.6 Hz, 2H), 0.98 (t, J = 7.6 Hz, 3H). MS: [ESI + H]+:
519.1. HPLC: 8.84 min
4-(8-Methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f ]-
purine-1(2H)-yl)butyl 3-(fluorosulfonyl)benzoate (14c). Prepared
from 12c and purified by column chromatography (first 30% DCM in
EtOAc). Further purification by another column (4:1 = methyl tert-
butyl ether/petroleum ether) gives the desired product as a white
solid (0.20 g, 0.37 mmol, 38%). 1H NMR (400 MHz, CDCl3): δ 8.85
(d, J = 7.2 Hz, 1H), 8.67 (s, 1H), 8.45 (d, J = 8.0 Hz, 1H), 8.21 (d, J =
8.0 Hz, 1H), 7.75 (t, J = 8.0 Hz, 1H), 6.97 (d, J = 2.4 Hz, 1H), 6.77
(dd, J = 7.2, 2.4 Hz, 1H), 4.49 (t, J = 6.4 Hz, 2H), 4.30 (t, J = 7.2 Hz,
2H), 4.08−4.01 (m, 2H), 3.95 (s, 3H), 2.10−2.00 (m, 2H), 2.00−
1.89 (m, 2H), 1.81−1.69 (m, 2H), 1.01 (t, J = 7.2 Hz, 3H). MS: [ESI
+ H]+: 533.1. HPLC: 9.14 min
General Procedure for the Synthesis of 1-(2-(1,3-Dioxoi-
soindolin-2-yl)alkyl)-8-methoxy-3-propyl-1H,3H-pyrido-[2,1-
f ]purine-2,4-dione (15a−c). To a mixture of the core (7) (0.8
mmol, 1 equiv), N-(bromoalkyl)phthalimide (1.2 mmol, 1.5 equiv),
and K2CO3 (1.2 mmol, 1.5 equiv) was added anhydrous DMF (8
mL). The mixture was refluxed at 100 °C. After completion of the
reaction, monitored by TLC (1% MeOH in CH2Cl2), the mixture was
concentrated in vacuo and diluted with EtOAc (30 mL). The organic
layer was washed with H2O (3 × 30 mL) and brine (15 mL), and
dried over MgSO4. The solvent was evaporated under reduced
pressure and the residue was purified by column chromatography
using 1% MeOH as an eluent to give 15a−c as solids.
1-(2-(1,3-Dioxoisoindolin-2-yl)ethyl)-8-methoxy-3-propyl-1H,3H-
pyrido-[2,1-f ]purine-2,4-dione (15a). Prepared from N-(2-
bromoethyl)phthalimide and purified by column chromatography to
give the desired product as a white solid (0.20 g, 0.44 mmol, 5%). 1H
NMR (CDCl3): δ 8.77 (d, J = 6.8 Hz, 1H), 7.73 (s, 2H), 7.64 (s, 2H),
6.69 (d, J = 14.0 Hz, 2H), 4.53 (s, 2H), 4.17 (s, 2H), 3.89 (d, J = 6.2
Hz, 2H), 3.85 (s, 3H), 1.58−1.45 (m, 3H), 0.86 (t, J = 7.2 Hz, 3H).
1-(2-(1,3-Dioxoisoindolin-2-yl)propyl)-8-methoxy-3-propyl-
1H,3H-pyrido-[2,1-f ]purine-2,4-dione (15b). Prepared from N-(3-
bromoethyl)phthalimide and purified by column chromatography to
give the desired product as a yellow solid (0.31 g, 0.66 mmol, 66%).
1H NMR (400 MHz, CDCl3): δ 8.81−8.75 (m, 1H), 7.86−7.76 (m,
2H), 7.73−7.61 (m, 2H), 6.80 (s, 1H), 6.72 (dd, J = 7.2, 2.4 Hz, 1H),
4.29 (t, J = 6.8 Hz, 2H), 4.04−3.93 (m, 2H), 3.90 (s, 3H), 3.86−3.78
(m, 2H), 2.35−2.20 (m, 2H), 1.78−1.60 (m, 2H), 1.06−0.87 (m,
3H).
1-(2-(1,3-Dioxoisoindolin-2-yl)butyl)-8-methoxy-3-propyl-
1H,3H-pyrido-[2,1-f ]purine-2,4-dione (15c). Prepared from N-(4-
bromoethyl)phthalimide and purified by column chromatography to
give the desired product as a white solid (0.37 g, 0.76 mmol, 96%). 1H
NMR (400 MHz, CDCl3): δ 8.82 (d, J = 7.2 Hz, 1H), 7.82 (dd, J =
5.2, 2.8 Hz, 2H), 7.70 (dd, J = 5.2, 2.8 Hz, 2H), 6.93 (d, J = 2.4 Hz,
1H), 6.74 (dd, J = 7.2, 2.4 Hz, 1H), 4.22 (d, J = 7.2 Hz, 2H), 4.04−
3.96 (m, 2H), 3.92 (s, 3H), 3.75 (d, J = 7.2 Hz, 2H), 1.95−1.85 (m,
2H), 1.85−1.77 (m, 2H), 1.74−1.65 (m, 3H), 0.97 (d, J = 7.6 Hz,
3H).
General Procedure for the Synthesis of 1-(2-Aminoalkyl)-8-
methoxy-3-propyl-1H,3H-pyrido-[2,1-f ]purine-2,4-dione
(16a−c). To a stirred suspension of 15a−c (0.66 mmol, 1 equiv) in
MeOH (8 mL) was added excess hydrazine monohydrate (4.8 mL, 99
mmol). The mixture was stirred for 2−4 h at reflux. After conversion
of the starting material, the mixture was cooled to room temperature.
The solvents were removed under vacuum and the residue was
dissolved in 2 M NaOH (aq.) (25 mL). This aqueous phase was
extracted three times with CH2Cl2 (25 mL). The organic layers were
combined, dried over MgSO4, and concentrated in vacuo to obtain
16a−c.
1-(2-Aminoethyl)-8-methoxy-3-propyl-1H,3H-pyrido-[2,1-f ]-
purine-2,4-dione (16a). Prepared from 15a and purified by column
chromatography to give the desired product as a white solid (0.13 g,
0.39 mmol, 90%). 1H NMR (400 MHz, CDCl3): δ 8.84 (d, J = 7.6
Hz, 1H), 6.95 (d, J = 2.4 Hz, 1H), 6.75 (dd, J = 7.2, 2.4 Hz, 1H), 4.27
(t, J = 6.4 Hz, 2H), 4.05−3.99 (m, 2H), 3.93 (s, 3H), 3.15 (t, J = 6.4
Hz, 2H), 1.78−1.67 (m, 2H), 0.99 (d, J = 7.6 Hz, 3H).
1-(3-Aminopropyl)-8-methoxy-3-propyl-1H,3H-pyrido-[2,1-f ]-
purine-2,4-dione (16b). Prepared from 15b and purified by column
chromatography to give the desired product as a white solid (0.25 g,
0.75 mmol, 97%). 1H NMR (400 MHz, CDCl3): δ 8.82 (d, J = 7.2
Hz, 1H), 6.95 (d, J = 2.4 Hz, 1H), 6.75 (dd, J = 7.6, 2.4 Hz, 1H), 4.29
(t, J = 6.8 Hz, 2H), 4.07−3.98 (m, 2H), 3.93 (s, 3H), 2.75 (t, J = 6.6
Hz, 2H), 1.98 (p, J = 6.6 Hz, 2H), 1.78−1.65 (m, 2H), 0.99 (t, J = 7.4
Hz, 3H).
1-(4-Aminobutyl)-8-methoxy-3-propyl-1H,3H-pyrido-[2,1-f ]-
purine-2,4-dione (16c). Prepared from 15c and purified by column
chromatography to give the desired product as a white solid (0.23 g,
0.66 mmol, 86%). 1H NMR (400 MHz, CDCl3): δ 8.84 (d, J = 7.6
Hz, 1H), 6.97 (d, J = 2.4 Hz, 1H), 6.75 (dd, J = 7.2, 2.4 Hz, 1H), 4.20
(t, J = 7.2 Hz, 2H), 4.06−3.98 (m, 2H), 3.92 (s, 3H), 2.77 (d, J = 6.8
Hz, 2H), 1.92−1.82 (m, 2H), 1.78−1.66 (m, 2H), 1.63−1.53 (m,
2H), 0.99 (t, J = 7.2 Hz, 3H).
4-((2-(8-Methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f ]-
purin-1(2H)-yl)ethyl)carbamoyl)benzenesulfonyl Fluoride (17a).
EDC (0.12 g, 0.60 mmol, 1.2 equiv) was dissolved in CHCl3 (4
mL). To this stirring solution was added the acid (9a) (0.11 g, 0.55
mmol, 1.1 equiv). The amine (16a) (0.16 g, 0.50 mmol, 1.0 equiv)
was suspended in CHCl3 (6 mL) and then was added dropwise via an
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automatic syringe at a rate of 0.2 mL min−1. The reaction was stirred
for 1.5 h at room temperature and monitored by TLC (CH2Cl2/
acetone = 3:2). After completion, the solvent was removed under
vacuum and the residue was redissolved in CHCl3 (40 mL). The
organic layer was washed with 1 M HCl (40 mL) and H2O (2 × 40
mL), dried over MgSO4, and concentrated in vacuo to obtain 17a as a
white solid (0.20 g, 0.39 mmol, 78%). 1H NMR (400 MHz, CDCl3):
δ 8.83 (d, J = 7.2 Hz, 1H), 8.07−8.00 (m, 5H), 6.91 (d, J = 2.4 Hz,
1H), 6.80 (dd, J = 7.2, 2.0 Hz, 1H), 4.62−4.55 (m, 2H), 4.03 (t, J =
7.6 Hz, 2H), 3.95 (s, 3H), 3.94−3.89 (m, 2H), 1.68 (sextet, J = 7.6
Hz, 2H), 0.97 (t, J = 7.2 Hz, 3H). MS: [ESI + H]+: 504.1. HPLC:
7.93 min.
4-((3(8-Methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f ]-
purin-1(2H)yl)propyl)carbamoyl)benzenesulfonyl Fluoride (17b). A
suspension of EDC (0.22 g, 0.80 mmol, 1.5 equiv) and 9a (0.16 g,
0.80 mmol 1.05 equiv) was dissolved in CH2Cl2 (4 mL). To this
stirring solution amine was added (16b) (0.25 g, 0.76 mmol, 1.0
equiv) at room temperature. The reaction was stirred for 2 h and
monitored by TLC (3% MeOH in CH2Cl2). After completion, the
solvent was removed in vacuo and the residue was dissolved in CHCl3
(40 mL). The organic layer was washed with 1 M HCl (40 mL) and
twice with H2O (2 × 40 mL), dried over MgSO4, and concentrated in
vacuo. The product was purified by column chromatography using 2%
MeOH in CH2Cl2 to afford the title compound as a white solid (0.26
g, 0.50 mmol, 66%). 1H NMR (400 MHz, CDCl3) δ: 8.86 (d, J = 7.2
Hz, 1H), 8.38 (t, J = 5.6 Hz, 1H), 8.25 (d, J = 8.4 Hz, 2H), 8.16 (d, J
= 8.4 Hz, 2H), 6.85 (d, J = 2.4 Hz, 1H), 6.81 (dd, J = 7.2, 2.4 Hz,
1H), 4.35 (t, J = 6.0 Hz, 2H), 4.05 (t, J = 7.6 Hz, 2H), 3.92 (s, 3H),
3.47 (q, J = 6.4 Hz, 2H), 2.19−2.13 (m, 2H), 1.73 (sextet, J = 7.6 Hz,
2H), 1.00 (t, J = 7.6 Hz, 3H). 13C NMR (600 MHz, DMSO-d6, 348
K) δ 164.0, 160.9, 153.4, 150.6, 150.5, 149.1, 141.3, 133.3 (d, J = 96
Hz), 128.5, 127.9, 127.3, 107.0, 99.8, 95.4, 55.7, 41.5, 40.6, 36.8, 27.1,
20.5, 10.6. MS: [ESI + H]+: 518.1. HRMS-ESI+: [M + H]+ calcd:
518.1510 found: 518.1540, C23H25O6N5FS. HPLC: 8.27 min.
4-((4-(8-Methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f ]-
purin-1(2H)-yl)butyl)carbamoyl)benzenesulfonyl Fluoride (17c).
Acid 9a (0.11 g, 0.53 mmol, 1.5 equiv) was dissolved in an excess
of thionyl chloride (20 mL) at 75 °C under nitrogen for 3 h. After
removal of solvent and other volatiles under vacuum, 10a was
obtained as a colorless oil. Subsequently, amine 16c (0.12 g, 0.35
mmol, 1.0 equiv), K2CO3 (0.073 g, 0.53 mmol, 1.5 equiv), and dry
DMF were added and the reaction as stirred at 40 °C overnight. After
completion of the reaction, 1 M HCl (200 mL) was added and
extracted with CH2Cl2 (150 mL). The organic layer was washed with
water (100 mL) and brine (100 mL). The organic layer was dried,
filtered, and concentrated in vacuo. The residue was purified by
column chromatography using CH2Cl2 with 1% methanol as the
eluent to give 17c as a white solid (5.0 mg, 0.0094 mmol, 4%). 1H
NMR (400 MHz, CDCl3): δ 8.87 (d, J = 7.6 Hz, 1H), 8.17 (d, J = 8.4
Hz, 2H), 8.09 (d, J = 8.4 Hz, 2H), 7.54 (brs, 1H), 6.85 (s, 1H), 6.80
(dd, J = 7.2, 2.4 Hz, 1H), 4.29 (t, J = 7.6 Hz, 2H), 4.06 (t, J = 7.6 Hz,
2H), 3.92 (s, 3H), 3.68 (q, J = 6.0 Hz, 2H), 2.01 (pent, J = 6.8 Hz,
2H), 1.84−1.70 (m, 4H), 1.02 (t, J = 7.6 Hz, 3H). MS: [ESI + H]+:
532.3. HPLC: 8.28 min.
3-((2-(8-Methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f ]-
purin-1(2H)-yl)ethyl)carbamoyl)benzenesulfonyl Fluoride (18a).
EDC (0.12 g, 0.60 mmol, 1.2 equiv) was dissolved in CHCl3 (4
mL). To this stirring solution was added acid 9b (0.11 g, 0.55 mmol,
1.1 equiv). Amine 16a (0.16 g, 0.50 mmol, 1.0 equiv) was suspended
in CHCl3 (6 mL) and then was added dropwise via an automatic
syringe at a rate of 0.2 mL min−1. The reaction was stirred for 3 h at
room temperature and monitored by TLC (CH2Cl2/acetone = 3:2).
After completion, the solvent was removed in vacuo and the residue
was resolubilized in CHCl3 (40 mL). The organic layer was washed
with 1 M HCl (40 mL) and twice with H2O (2 × 40 mL), dried over
MgSO4, and concentrated in vacuo to give 18a as a white solid (0.17
g, 0.35 mmol, 70%). 1H NMR (400 MHz, CDCl3): δ 8.81 (d, J = 7.6
Hz, 1H), 8.37 (s, 1H), 8.29 (d, J = 8.0 Hz, 1H), 8.11 (d, J = 7.6 Hz,
1H), 8.04 (br s, 1H), 7.71 (t, J = 8.0 Hz, 1H), 7.02 (d, J = 2.4 Hz,
1H), 6.77 (dd, J = 7.6, 2.4 Hz, 1H), 4.61−4.54 (m, 2H), 4.03 (t, J =
7.6 Hz, 2H), 3.96 (s, 3H), 3.94−3.89 (m, 2H), 1.76−1.63 (m, 2H),
0.97 (t, J = 7.6 Hz, 3H). MS: [ESI + H]+: 504.1. HPLC: 7.67 min.
3-((3-(8-Methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f ]-
purin-1(2H)-yl)propyl)carbamoyl) benzenesulfonyl Fluoride (18b).
Acid 9b (0.42 g, 2.0 mmol, 3.0 equiv) was dissolved in thionyl
chloride (20 mL) and stirred for 3 h at 75 °C. The thionyl chloride
was evaporated and the residue was co-evaporated twice with toluene.
Then, amine 14b (0.23 mg, 0.7 mmol, 1.00 equiv), K2CO3 (0.073 g,
0.53 mmol, 1.5 equiv), and dry DMF were added and the reaction was
stirred at 40 °C overnight. 1 M HCl (200 mL) was added and
extracted with CH2Cl2 (150 mL). The organic layer was washed with
water (100 mL) and brine (100 mL). The organic layer was dried,
filtered, and concentrated in vacuo. The residue was purified by
column chromatography using CH2Cl2 with 1% methanol as the
eluent to give 18b as a white solid (0.0050 g, 0.01 mmol, 2.7%). 1H
NMR (400 MHz, CDCl3) δ: 8.88 (d, J = 7.2 Hz, 1H), 8.68 (s, 1H),
8.55−8.50 (m, 2H), 8.20 (d, J = 8.0 Hz, 1H), 7.82 (t, J = 8 Hz, 2H),
7.00 (d, J = 2.4 Hz, 1H), 6.80 (dd, J = 7.2, 2.4 Hz, 1H), 4.33 (t, J =
6.0 Hz, 2H), 4.05 (t, J = 7.6 Hz, 2H), 3.94 (s, 3H), 3.47 (q, J = 6.0
Hz, 2H), 2.17−2.12 (m, 2H), 1.74 (sextet, J = 7.6 Hz, 2H), 1.00 (t, J
= 7.6 Hz, 3H). MS: ESI [M + H]+: 518.1 HPLC: 8.28 min.
3-((4-(8-Methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f ]-
purin-1(2H)-yl)butyl)carbamoyl)benzenesulfonyl Fluoride (18c).
EDC (0.13 g, 0.69 mmol, 1.2 equiv) was dissolved in CH2Cl2 (3
mL). Acid 9b (0.13 g, 0.63 mmol, 1.1 equiv) was added to this
solution and the mixture was stirred. Amine 16c (0.20 g, 0.57 mmol, 1
equiv) was dissolved in CHCl3 (8 mL) and added dropwise via an
automatic syringe at a rate of 0.2 mL min−1 to the stirring solution.
After 3 h at room temperature, the reaction was completed and the
mixture was concentrated in vacuo. The residue was dissolved in
CH2Cl2 (40 mL) and washed with 1 M HCl (40 mL) and twice with
H2O (2 × 40 mL). The organic layer was dried over MgSO4 and
concentrated in vacuo. Purification by column chromatography
(CH2Cl2/acetone = 3:2) gave 18c as a white solid (0.14 g, 0.26
mmol, 47%). 1H NMR (400 MHz, CDCl3): δ 8.84 (d, J = 7.2 Hz,
1H), 8.54 (s, 1H), 8.36 (d, J = 7.6 Hz, 1H), 8.12 (d, J = 7.6 Hz, 1H),
7.72 (t, J = 7.6 Hz, 1H), 7.62 (br s, 1H), 6.84 (s, 1H), 6.80−6.70 (m,
1H), 4.27 (t, J = 7.2 Hz, 2H), 4.04 (t, J = 8.0 Hz, 2H), 3.89 (s, 3H),
3.74−3.60 (m, 2H), 2.07−1.92 (m, 2H), 1.85−1.64 (m, 4H), 0.98 (t,
J = 7.2 Hz, 3H). MS: [ESI + H]+: 532.3. HPLC: 8.21 min.
N-(3-(8-Methoxy-2,4-dioxo-3-propyl-3,4-dihydropyrido[2,1-f ]-
purin-1(2H)-yl)propyl)-4-(methylsulfonyl)benzamide (19). To a
solution of EDC (0.061 g, 0.32 mmol, 1.2 equiv) in CHCl3 (5 mL)
was added 4-(methylsulfonyl)benzoic acid (0.060 g, 0.30 mmol, 1.1
equiv). Amine 16b (0.090 g, 0.27 mmol, 1 equiv) was taken up in
CHCl3 (5 mL) and was subsequently added dropwise via an
automatic syringe at a rate of 0.15 mL min−1. The reaction was stirred
at room temperature and monitored by TLC (4% MeOH in CH2Cl2).
After 3 h, the reaction was completed and CHCl3 (50 mL) was added.
The organic layer was washed with 1 M HCl (60 mL), H2O (60 mL),
and brine (60 mL), dried over MgSO4, and concentrated under
vacuum. The product was purified by column chromatography using
2% MeOH in CH2Cl2 to afford the title compound (0.075 g, 0.14
mmol, 54%). 1H NMR (400 MHz, CDCl3): δ 8.86 (d, J = 7.2 Hz,
1H), 8.36 (t, J = 5.6 Hz, 1H), 8.19 (d, J = 8.4 Hz, 2H), 8.09 (d, J = 8.4
Hz, 2H), 6.90−6.71 (m, 2H), 4.45−4.28 (m, 2H), 4.13−3.99 (m,
2H), 3.91 (s, 3H), 3.55−3.41 (m, 2H), 3.11 (s, 3H), 2.27−2.09 (m,
2H), 1.83−1.61 (m, 2H), 1.00 (t, J = 7.4 Hz, 3H). 13C NMR (600
MHz, DMSO-d6, 318 K): δ 164.7, 161.1, 153.5, 150.7, 150.6, 149.3,
142.8, 138.9, 127.9, 127.5, 126.7, 107.4, 99.9, 95.4, 56.0, 43.2, 41.6,
40.8, 36.8, 27.4, 20.7, 10.9. MS: [ESI + H]+: 514.2. HRMS-ESI+: [M
+ H]+ calcd: 518.1760 found: 518.1791, C24H28O6N5S. HPLC: 6.89
min.
Computational Studies. All calculations were performed using
the Schrodinger Suite.31 Since compound 17b shares high similarity
with the ligands on which we previously published,7 the same
homology model based on the high-resolution antagonist-bound
crystal structure of the adenosine A2A receptor (PDB: 4EIY
27) was
used for the docking studies performed here. Based on these proposed
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docking poses, we used induced fit docking32 with core constraints on
the pyridopurinedione to dock the different ligands.
Biology. [3H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-
1H-imidazo[2,1-i]-purin-5-one ([3H]PSB-11, specific activity 56 Ci
mmol−1) was a gift from Prof. C. E. Müller (University of Bonn,
Germany). Unlabeled PSB-11, 1-deoxy-1-[6-[3- and 2-chloro-N6-(3-
iodobenzyl)-adenosine-5′-N-methyluronamide]] (2-Cl-IB-MECA)
were purchased from Tocris Ltd. (Abingdon, U.K.). 5′-N-Ethyl-
carboxamidoadenosine (NECA) was purchased from Sigma-Aldrich
(Steinheim, Germany). Adenosine deaminase was purchased from
Boehringer Mannheim (Mannheim, Germany). Bicinchoninic acid
(BCA) and BCA protein assay reagents were purchased from Pierce
Chemical Company (Rockford, IL). Chinese hamster ovary (CHO)
cells stably expressing the human A3 adenosine receptor (CHOhA3)
were a gift from Dr. K.-N. Klotz (University of Würzburg, Germany).
All other chemicals were obtained from standard commercial sources
and were of analytical grade.
Cell Culture and Membrane Preparation. Chinese hamster
ovary (CHO) cells, stably expressing the human A3 adenosine
receptor (CHOhA3), were cultured and membranes were prepared
and stored as previously reported.7,33 Protein determination was
performed based on the bicinchoninic acid (BCA) method.34
Y265F7.36 Site-Directed Mutagenesis. The single tyrosine
mutation introduced in TM7 of the hA3AR was performed with the
QuickChange II Site-Directed Mutagenesis system (Stratagene,
Huizen, The Netherlands). The wild-type pcDNA3.1(+)-A3AR
plasmid DNA with N-terminal 3 × HA-tag was used as a template
for polymerase chain reaction (PCR) mutagenesis. Mutant primers
for directional PCR product cloning were designed using the online
Quickchange primer design program (Agilent Technologies, Santa
Clara, CA) and obtained from Eurogentec (Maastricht, The
Netherlands). Forward primer used for this procedure was 5′-
cacagcttgtgctgttcatgggcatcctgct-3′ and the reverse primer was 5′-
agcaggatgcccatgaacagcacaagctgtg-3′. All DNA sequences were verified
by Sanger sequencing at LGTC (Leiden, The Netherlands).
Transient Expression of Wild Type (WT) and Mutant
Receptors in CHO-K1 Cells. CHO-K1 cells were seeded into 150
mm culture dishes to achieve 60% confluence in the presence of 20
mL culture medium consisting of Dulbecco’s modified Eagle’s
medium/F12 (1:1) supplemented with 10% (v/v) newborn calf
serum, streptomycin (50 μg mL−1), and penicillin (50 IU mL−1). The
cells were transfected approximately 24 h later with plasmid DNA (20
μg of DNA/dish) by the PEI method35 (PEI/DNA = 3:1) and left for
24 h. Subsequently, the medium was removed and fresh medium
containing 5 mM sodium butyrate was added (to enhance the
receptor expression level36), and cells were grown for an additional 24
h at 37 °C and 5% CO2. Membrane preparation followed the
procedure described above for the CHO cell membranes stably
expressing the hA3AR.
7,33
Radioligand Displacement Assay. Radioligand displacement
experiments were performed as in previously published methods.7
Membrane aliquots containing 15 μg of protein were incubated in a
total volume of 100 μL assay buffer (50 mM Tris−HCl, 5 mM MgCl2,
s upp l emen t ed w i t h 0 . 01% 3 - [ (3 - cho l am idop ropy l ) -
dimethylammonio]-1-propanesulfonate and 1 mM ethylenediamine-
tetraacetic acid (EDTA), pH 7.4) at 25 °C for 120 min. Displacement
experiments were performed using six concentrations of competing
antagonist in the presence of ∼10 nM [3H]PSB-11. Nonspecific
binding was determined in the presence of 100 μm NECA and
represented less than 10% of total binding. Incubation was terminated
by rapid filtration performed on 96-well GF/B filter plates
(PerkinElmer, Groningen, the Netherlands) in a PerkinElmer
Filtermate-harvester (PerkinElmer, Groningen, the Netherlands).
After the filter plate was dried at 55 °C for 30 min, the filter-bound
radioactivity was determined by scintillation spectrometry using a
2450 MicroBeta2 Plate Counter (PerkinElmer, Boston, MA).
Radioligand Competition Association Assay. The competi-
tion association assay was performed by incubation of ∼10 nM
[3H]PSB-11 in the absence or presence of the competing hA3AR
antagonist at its IC50 concentration with membrane aliquots. The
amount of receptor-bound radioligand was determined at different
time points up to 240 min. Incubations were terminated and samples
were obtained as described under the Radioligand Displacement
Assay.
[35S] GTPγS Binding Assay. The assays were started by adding 15
μg of homogenized CHOhA3 membranes in an ice-cold assay buffer
to a total volume of 80 μL containing 50 mM Tris−HCl buffer, 5 mM
MgCl2, 1 mM EDTA, 0.05% bovine serum albumin and 1 mM
dithiothreitol, 100 mM NaCl, pH 7.4, supplemented with 1 μm GDP
and 5 μg saponin. The assays were performed in a 96-well plate
format, where stock solutions of the compounds were added to a total
volume of 100 μL using an HP D300 Digital Dispenser (Tecan,
Ma ̈nnedorf, Switzerland). The final concentration of dimethyl
sulfoxide (DMSO) per assay point was ≤0.1%. The basal level of
[35S] GTPγS binding was determined in the absence of the ligand,
whereas the maximal level of [35S] GTPγS binding was determined in
the presence of 10 μm 2-Cl-IB-MECA. For the insurmountability
experiments, membrane preparations were preincubated with or
without antagonists (0.1-,1-, 3-, 10-fold Ki values) for 60 min at 25 °C,
prior to the addition of 2-Cl-IB-MECA (10 μm to 0.1 nM) and 20 μL
[35S] GTPγS (final concentration ∼0.3 nM), after which incubation
continued for another 30 min at 25 °C. For the surmountability
(control) experiments, antagonists (1-, 3-, 10-fold Ki values) and 2-Cl-
IB-MECA (10 μm to 0.1 nM) were co-incubated with [35S] GTPγS
for 30 min at 25 °C. For all experiments, incubations were terminated
and samples were obtained as described under the Radioligand
Displacement Assay, using GF/B filters (Whatman International,
Maidstone, U.K.).
Data Analysis. All experimental data were analyzed using the
nonlinear regression curve fitting program GraphPad Prism 7.0
(GraphPad Software, Inc., San Diego, CA). Data from the radioligand
displacement assays were fit into one-site binding mode, and the
obtained IC50 values were converted into Ki values using the Cheng−
Prusoff equation to determine the affinity of the ligands.37 The
observed association rate constants (kobs) derived from both assays
were obtained by fitting association data using one-phase exponential
association. The dissociation rate constants were obtained by fitting
dissociation data to a one phase exponential decay model. The kobs
values were converted into association rate constants (kon) using the
equation kon = (kobs − koff)/[L], where [L] is the amount of
radioligand used for the association experiments. Association and
dissociation rate constants for unlabeled compounds were calculated
by fitting the data into the competition association model using
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where X is the time (min), Y is the specific [3H]PSB-11 binding
(DPM), k1 and k2 are the kon (M
−1 min−1) and koff (min
−1) of
[3H]PSB-11, respectively, Bmax is the total binding (DPM), L is the
radioligand concentration (nM), and I is the concentration of the
unlabeled competitor (nM). Association and dissociation rate
constants for [3H]PSB-11 (k1 = 0.281 ± 0.04 × 10
8 M−1 min−1
and k2 = 0.3992 ± 0.02 min−1) were obtained from Xia et al.
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that, the k3, k4, and Bmax were calculated, where k3 represents the kon
(M−1 min−1) of the unlabeled ligand, k4 stands for the koff (min
−1) of
the unlabeled ligand and Bmax equals the total binding (DPM). All
competition association data were globally fitted. The residence time
(RT, in min) was calculated using the equation RT = 1/koff, as koff
values are expressed in min−1. [35S] GTPγS binding curves were
analyzed by nonlinear regression using “log (agonist) vs response−
variable slope” to obtain potency, inhibitory potency, or efficacy
values of agonists and antagonists (EC50 and Emax, respectively). In the
(in)surmountability assays, Schild EC50 shift equations were used to
obtain Schild-slopes and pA2 values. All experimental values obtained
are means of three independent experiments performed in duplicate.
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(33) Heitman, L. H.; Göblyös, A.; Zweemer, A. M.; Bakker, R.;
Mulder-Krieger, T.; van Veldhoven, J. P. D.; de Vries, H.; Brussee, J.;
IJzerman, A. P. A series of 2,4-disubstituted quinolines as a new class
of allosteric enhancers of the adenosine A3 receptor. J. Med. Chem.
2009, 52, 926−931.
(34) Smith, P. K.; Krohn, R. I.; Hermanson, G. T.; Mallia, A. K.;
Gartner, F. H.; Provenzano, M. D.; Fujimoto, E. K.; Goeke, N. M.;
Olson, B. J.; Klenk, D. C. Measurement of protein using bicinchoninic
acid. Anal. Biochem. 1985, 150, 76−85.
(35) Boussif, O.; Lezoualch, F.; Zanta, M. A.; Mergny, M. D.;
Scherman, D.; Demeneix, B.; Behr, J. P. A versatile vector for gene
and oligonucleotide transfer into cells in culture and in-vivo -
polyethylenimine. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 7297−7301.
(36) Gorman, C. M.; Howard, B. H.; Reeves, R. Expression of
recombinant plasmids in mammalian-cells is enhanced by sodium-
butyrate. Nucleic Acids Res. 1983, 11, 7631−7648.
(37) Yung-Chi, C.; Prusoff, W. H. Relationship between the
inhibition constant (KI) and the concentration of inhibitor which
causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem.
Pharmacol. 1973, 22, 3099−3108.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.8b02026
J. Med. Chem. 2019, 62, 3539−3552
3552
